The Parkinson Progression Marker Initiative (PPMI)

Kenneth Marek, Danna Jennings, Shirley Lasch, Andrew Siderowf, Caroline Tanner, Tanya Simuni, Chris Coffey, Karl Kieburtz, Emily Flagg, Sohini Chowdhury, Werner Poewe, Brit Mollenhauer, Todd Sherer, Mark Frasier, Claire Meunier, Alice Rudolph, Cindy Casaceli, John Seibyl, Susan Mendick, Norbert SchuffYing Zhang, Arthur Toga, Karen Crawford, Alison Ansbach, Pasquale de Blasio, Michele Piovella, John Trojanowski, Les Shaw, Andrew Singleton, Keith Hawkins, Jamie Eberling, David Russell, Laura Leary, Stewart Factor, Barbara Sommerfeld, Penelope Hogarth, Emily Pighetti, Karen Williams, David Standaert, Stephanie Guthrie, Robert Hauser, Holly Delgado, Joseph Jankovic, Christine Hunter, Matthew Stern, Baochan Tran, Jim Leverenz, Marne Baca, Sam Frank, Cathi Ann Thomas, Irene Richard, Cheryl Deeley, Linda Rees, Fabienne Sprenger, Elisabeth Lang, Holly Shill, Sanja Obradov, Hubert Fernandez, Adrienna Winters, Daniela Berg, Katharina Gauss, Douglas Galasko, Deborah Fontaine, Zoltan Mari, Melissa Gerstenhaber, David Brooks, Sophie Malloy, Paolo Barone, Katia Longo, Tom Comery, Bernard Ravina, Igor Grachev, Kim Gallagher, Michelle Collins, Katherine L. Widnell, Suzanne Ostrowizki, Paulo Fontoura, F. Hoffmann La-Roche, Tony Ho, Johan Luthman, Marcel van der Brug, Alastair D. Reith, Peggy Taylor

Research output: Contribution to journalReview article

541 Scopus citations

Abstract

The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials. The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally for clinical, imaging and biospecimen biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites. All study data will be integrated in the PPMI study database and will be rapidly and publically available through the PPMI web site- www.ppmi-info.org. Biological samples including longitudinal collection of blood, cerebrospinal fluid (CSF) and urine will be available to scientists by application to an independent PPMI biospecimen review committee also through the PPMI web site. PPMI will rely on a partnership of government, PD foundations, industry and academics working cooperatively. This approach is crucial to enhance the potential for success of this ambitious strategy to develop PD progression biomarkers that will accelerate research in disease modifying therapeutics.

Original languageEnglish (US)
Pages (from-to)629-635
Number of pages7
JournalProgress in Neurobiology
Volume95
Issue number4
DOIs
StatePublished - Dec 1 2011

Keywords

  • Alpha synuclein
  • Biomarker
  • Cerebrospinal fluid
  • Diffusion tensor imaging
  • Dopamine transporter imaging

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'The Parkinson Progression Marker Initiative (PPMI)'. Together they form a unique fingerprint.

  • Cite this

    Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., Poewe, W., Mollenhauer, B., Sherer, T., Frasier, M., Meunier, C., Rudolph, A., Casaceli, C., Seibyl, J., Mendick, S., ... Taylor, P. (2011). The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 95(4), 629-635. https://doi.org/10.1016/j.pneurobio.2011.09.005